skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Strategic industry insight

Contact us to get more information

Construct winning strategies that anticipate where value will lie. In Vivo’s in-depth analysis spans influential  deals, R&D, commercial and market access strategies. 

How it helps 

With In Vivo, you’ll benefit from:

  • Insight about the key players in the industry
  • In-depth coverage of company strategies
  • Expert analysis of deal making, R&D, commercial, market access and finance strategies and trends
  • Exclusive insider insight and thought leadership
  • Help with specific questions from our renowned Ask-the-Analyst™ service



How it works

Access mission-critical information via a simple-to-use interface. And if you need to need to find out more about developments or pharmaceutical industry trends to support presentations, proposals or business-critical decisions, you can access our worldwide network of expert analysts through our acclaimed Ask-the-Analyst™ service. 

Plus, you can identify threats and opportunities using our Execs on the Move feature, which tracks the company movements of senior executives.

What's included

Pharma Intelligence: latest

  • In Vivo

    Broader Capabilities Keep Consort On Top At Device End Of Drug Delivery

    By Ashley Yeo 06 Sep 2018

    Drug delivery technology specialist Consort Medical has capitalized on device respiratory expertise for 50 years, but a renewed focus on strategic expansion has seen it make an IP play, move into the pharma side and target other delivery formats for global pharma industry customers. Its enhanced capabilities will keep rivals on their toes.

    Topic Drug review Drug approval

  • In Vivo

    World In Motion The Shape Of The New Health Care Technology Ecosystem In 2022

    By Ashley Yeo 22 Aug 2018

    The health products industry, methods of care delivery and even the public's expectations for improved tools to prevent, monitor and treat disease have transformed dramatically in the past five years. The changes anticipated over a similar period ahead are potentially even more marked, with business continuity impacts for medtech and pharma concerns, according to Deloitte LLP experts who were on the circuit at health care industry events in Germany and the UK this spring.

    Topic Business strategies Digital Health

  • In Vivo

    Pharma’s New R&D Models: Federating Innovation

    By Melanie Senior 22 Aug 2018

    Experiments are underway to solve pharma’s well-documented R&D productivity crisis. The industry is no longer focused only on buying new drugs via M&A, or on outsourcing discovery. Companies are also building new channels through which to access innovation, setting up different kinds of partnerships, and using new kinds of data. The shift involves re-thinking pharma’s place in healthcare.

    Topic Research Drug development landscape

  • In Vivo

    Ortho Demand Pull: DePuy Synthes Shaping Its Digital And Robotic Surgery Strategy Around Patient Needs

    By Ashley Yeo 22 Aug 2018

    Johnson & Johnson's DePuy Synthes orthopedic business has taken a measured view of digital and robotic capabilities, rather than acquiring assets that perhaps do not fully meet its strategic needs. For the business's global R&D head Euan Thomson, any new technology must augment the group's abilities to drive meaningful outcomes.

    Topic Digital Health

  • In Vivo

    Bayer’s US Playbook: The Smart Way To Top-Line Growth

    By William Looney 22 Aug 2018

    The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.

    Topic Business strategies Company analysis

  • In Vivo

    Back To The Future: Novo’s Sørensen Reflects On CEO Years And Tasks Ahead For Industry

    By Lucie Ellis 22 Aug 2018

    Lars Rebien Sørensen scrutinizes the pharmaceutical industry and shares with In Vivo his vision for the future of the Novo Nordisk Foundation. With 16 years as CEO of Novo Nordisk under his belt, as well as many more years in leadership roles at the Danish company, Sørensen reflects on the past and gives his predictions for the future of the innovative drug development sector.

    Topic Drug development landscape Business strategies

  • In Vivo

    Cancer's New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?

    By William Looney 22 Aug 2018

    The 16 million survivors of cancer in the US today form a restless constituency with its own disparate set of interests – and by sheer weight of numbers is beginning to direct changes to medical practice that pose both risks and opportunity for biopharma.

    Topic Cancer

  • In Vivo

    True Innovation In Women's Health Hindered Because Conditions Are Not Fatal

    By Lucie Ellis 17 Aug 2018

    Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.

    Topic Drug approval Drug review

  • In Vivo

    NASH: Flying The Plane While Building It

    By Amama Sadiq, Iliyana P. Atanasova, Katherine J. Franklin 03 Aug 2018

    Drug development for nonalcoholic steatohepatitis (NASH), a form of liver disease, is a game of incomplete information: pipeline evolution is occurring in parallel with continued efforts to better understand and manage the disease. To date, no therapy for patients with NASH has been approved and consequences of the condition can be severe, including cirrhosis and hepatocellular carcinoma.

    Topic Clinical trials

  • In Vivo

    Cancer Vaccines: Is There A Future Beyond Trial And Error?

    By William Looney 12 Jul 2018

    Strong foundational research in immunology and some promising early phase trial results have so far failed to expedite the validation of vaccines to treat cancer. In Vivo examines biopharma’s enduring optimism about the future of cancer vaccinology, including a closer look at one company’s platform to tackle the incurable malignancies that beset the mother of all organs: the human brain.

    Topic Cancer Vaccines

  • In Vivo

    Repositioning Market Access: A Function Fit For Purpose In A New Era Of Costly Cures

    By William Looney 15 May 2018

    On October 5, In Vivo convened a group of top market-access specialists and industry and investment analysts to consider a central strategic challenge facing all innovators in biopharma: how to pay for the next wave of cures. Finding the answer first depends on a rebranding of the function itself – it’s not market access to products; it’s patient access to progress.

    Topic Strategy

  • In Vivo

    Pharma Sourcing And Procurement: The New Strategy Of Spend

    11 May 2018

    Just what does a strategic approach to sourcing and procurement mean for today’s biopharma enterprise?In Vivotalks to the practice leaders at two diversely representative companies – Adamas Pharmaceuticals and Roivant Sciences – to identify four essential characteristics of “best in class” purchasing performance: (1) Think big – be strategic. (2) Buy better – add value.  (3) Work fast – spend forward. (4) Reach out earn the business.

    Topic BioPharmaceutical

  • In Vivo

    Business As Usual Is Not A Vision For The Future - The Value-Based Shift Is Underway

    By Ashley Yeo 11 May 2018

    Value is a concept that is increasingly embraced by providers and payers, as well as medtech manufacturers. Leading providers are organizing around value, changing their models and thereby inviting medtech manufacturers to adapt to the post fee-for-service era. Some, like Medtronic, are at the head of the game.

  • In Vivo

    Success in Oncology Infographic

    10 May 2018

    As events and developments in oncology rapidly shift and unfold, it’s more critical than ever to stay vigilant and agile to stay ahead.Understand these market disruptions and react to them with confidence with the data in Innovation in Oncology, the vital, free infographic from In Vivo.

    Topic Cancer

  • In Vivo

    Success In Oncology Whitepaper

    10 May 2018

    Looking for your path to success in oncology? Stay on top of the rapidly accelerating complexity of oncology drug development with the crucial insights into cancer treatments that only In Vivo can provide – now yours as a free download.

    Topic Cancer

Meet the team

Editor

Alexandra Shimmings

Editor, Executive Editor, Pharma Insights
Alexandra Shimmings

Alexandra specializes in

  • Biotech

+21 year(s) experience

Editor

Nancy Dvorin

Editor, Managing editor
Nancy Dvorin

Nancy specializes in

  • Medtech
  • Market Intelligence

+19 year(s) experience

Analyst

Amanda Micklus

Analyst, Principal Analyst

Connecticut

Amanda Micklus

Amanda specializes in

  • Oncology
  • Business Development & Licensing
  • Commercial Strategy

+18 year(s) experience

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: